Form 6-K TRINITY BIOTECH PLC For: Jul 02
Tweet
Share
E-mail
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
|
|
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2026
TRINITY BIOTECH PLC
(Name of Registrant)
IDA Business Park
Bray, County. Wicklow, Ireland
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
EXPLANATORY NOTE
On July 2, 2026, the Company unveiled clinical trial data related to its CGM+ solution. A copy of the press release is being furnished herewith as Exhibit 99.1
EXHIBIT INDEX
Exhibit |
| Description |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| TRINITY BIOTECH PLC |
| |
|
| Trinity Biotech plc |
|
|
| (Registrant) |
|
|
|
|
|
| By: | /s/ Paul Murphy |
|
|
| Paul Murphy |
|
|
| Interim Chief Financial Officer |
|
Date: July 2, 2026
|
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology
- US FOODS TEAMSTERS UNANIMOUSLY RATIFY FIRST CONTRACT
- Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
